Compugen (CGEN) Stock Price Down 11.6%

Shares of Compugen Ltd. (NASDAQ:CGEN) traded down 11.6% on Monday . The stock traded as low as $3.40 and last traded at $3.51. 521,613 shares changed hands during trading, an increase of 199% from the average session volume of 174,204 shares. The stock had previously closed at $3.97.

Several analysts recently weighed in on the company. ValuEngine downgraded Compugen from a “hold” rating to a “sell” rating in a research note on Friday, December 21st. Zacks Investment Research downgraded Compugen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 8th. Finally, Oppenheimer set a $9.00 target price on Compugen and gave the company a “buy” rating in a research note on Tuesday, February 26th.

The firm has a market cap of $182.08 million, a P/E ratio of -8.66 and a beta of 2.55.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings results on Tuesday, February 26th. The biotechnology company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.05. As a group, equities analysts predict that Compugen Ltd. will post -0.57 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Morgan Stanley boosted its position in Compugen by 2.8% in the 3rd quarter. Morgan Stanley now owns 998,173 shares of the biotechnology company’s stock valued at $3,843,000 after buying an additional 27,240 shares during the last quarter. Taylor Frigon Capital Management LLC boosted its position in Compugen by 17.2% in the 4th quarter. Taylor Frigon Capital Management LLC now owns 690,262 shares of the biotechnology company’s stock valued at $1,498,000 after buying an additional 101,212 shares during the last quarter. Defender Capital LLC. bought a new position in Compugen in the 4th quarter valued at $630,000. Renaissance Technologies LLC boosted its position in Compugen by 8.2% in the 3rd quarter. Renaissance Technologies LLC now owns 265,100 shares of the biotechnology company’s stock valued at $1,021,000 after buying an additional 20,200 shares during the last quarter. Finally, Matrix Asset Advisors Inc. NY boosted its position in Compugen by 20.8% in the 4th quarter. Matrix Asset Advisors Inc. NY now owns 104,500 shares of the biotechnology company’s stock valued at $227,000 after buying an additional 18,000 shares during the last quarter. 22.87% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece was posted by Modern Readers and is the property of of Modern Readers. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.modernreaders.com/news/2019/04/17/compugen-cgen-stock-price-down-11-6.html.

About Compugen (NASDAQ:CGEN)

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

See Also: Sell-Side Analysts

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.